Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study
Sponsor: Ariston Pharmaceuticals, Inc.
This PHASE2 trial investigates Migraine and Migraine Disorders and is currently ongoing. Ariston Pharmaceuticals, Inc. leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ariston Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ashford, United Kingdom , Brahenkatu 11D, Turku, Finland , Devon, United Kingdom , East Horsley, United Kingdom , Farnworth BL4 9QZ Bolton, United Kingdom , Fowey, United Kingdom , Geerdinksweg 141, Hengelo, Netherlands , Geldrop, Netherlands , Groot Wezenland 20, Netherlands , Hameenkatu 18 6th Floor, Tampere, Finland and 9 more locations